Milestone Pharmaceuticals Inc. (MIST)
- Previous Close
1.6400 - Open
1.6200 - Bid 1.6100 x 100
- Ask 1.7300 x 100
- Day's Range
1.6050 - 1.6927 - 52 Week Range
1.3300 - 4.4900 - Volume
34,727 - Avg. Volume
323,700 - Market Cap (intraday)
86.634M - Beta (5Y Monthly) 1.77
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3900 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.50
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
www.milestonepharma.comRecent News: MIST
Performance Overview: MIST
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MIST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MIST
Valuation Measures
Market Cap
86.63M
Enterprise Value
72.41M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
70.02
Price/Book (mrq)
5.17
Enterprise Value/Revenue
72.41
Enterprise Value/EBITDA
-1.27
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-51.01%
Return on Equity (ttm)
-143.61%
Revenue (ttm)
1M
Net Income Avi to Common (ttm)
-59.69M
Diluted EPS (ttm)
-1.3900
Balance Sheet and Cash Flow
Total Cash (mrq)
66M
Total Debt/Equity (mrq)
308.72%
Levered Free Cash Flow (ttm)
-28.29M